2023年6月23日

RxLightning——一個創造者的行業首個全麵精簡專業藥物平台訪問和負擔能力——宣布關閉一係列1750萬美元投資來支持公司的成長,進一步消除阻礙拯救生命的治療。這一輪融資是由LRVHealth, McKesson企業和現有投資者的參與諾華(dRx資本),Onco360 (BrightSpring衛生服務)、赫斯特公司,HealthX企業。這些投資帶來RxLightning自《盜夢空間》的總資金為2050萬美元。通過RxLightning,衛生保健提供者——從這些練習獨立診所大型衛生係統——利用簡化工作流完成多步專業藥物新員工培訓過程在幾分鍾內。和公司的MedAccess生態係統是一個集成的平台,為病人提供了透明訪問和可購性旅程為醫生、患者、專業藥房,藥品製造商,減少行政負擔和使新員工培訓支持。專業藥物市場代表在美國超過一半的藥物支出總額,reaching $301 billion in 2021, according to data from the U.S. Department of Health and Human Services. And despite this growing reliance on advanced therapies, accessing these medications remains a slow, manual, and costly process. Plus every specialty medication currently requires a custom paper form that a provider or patient must complete. These forms are then pushed through a manual process outside the electronic health record (EHR), which can result in significant care delays. RxLightning is known as the single destination to enroll patients for any specialty medication – brand or generic – at any specialty pharmacy. And the company has digitized forms for over 1,200 specialty drugs with custom logic and smart-pick menus, and continuously adds forms for new medications as they enter the market. Plus the modular platform automates the FDA’s Risk Evaluation and Mitigation Strategies (REMS) program, confirms patient eligibility and coverage, and streamlines enrollment in financial assistance programs to further eliminate access barriers. Through RxLightning, providers and patients can complete the entire onboarding process in minutes or hours rather than days or weeks. In connection with this funding round, LRVHealth’s Josh Flum and McKesson Ventures’ Carrie Williams will join RxLightning’s board of directors alongside HealthX Ventures’ Mark Bakken, former Walgreens executive Brad Fluegel, and Julia Regan. RxLightning is available at no cost to healthcare providers and helps them get patients started on specialty medications at lightning speed. KEY QUOTES: “Many people have tried to fix the slow, manual specialty medication onboarding process, but they’ve approached it with a single drug, pharmacy, or isolated part of the process in mind. RxLightning is the first to provide an end-to-end solution that covers the entire market – from every medication and destination to every stakeholder in the process. This new investment will help us further scale our medication access capabilities, support infrastructure and personnel growth, and maintain the unprecedented rate at which we’ve grown our partner base – all while receiving strategic guidance from leading industry experts.” — Julia Regan, CEO and founder at RxLightning “RxLightning has gone far beyond creating a digital experience that replaces paper forms, and has created a first-of-its-kind ecosystem that connects every part of the specialty medication process. As the specialty market continues to grow and transform the treatment of diseases, RxLightning will play an important role in improving access while minimizing cost and burden on the system. We’re proud to be standing alongside such a talented team on this journey.” — Josh Flum, managing partner at LRVHealth “RxLightning addresses the tedious administrative burden faced by providers when trying to initiate patients on specialty medications. The complexity will only increase as new drugs entering the market require even more nuanced clinical, financial, and logistical considerations to ensure patients get access to medications as efficiently as possible. It’s rare to find a company that is so truly aligned across pharma, payer, provider, and patient needs.” — Carrie Williams, partner for McKesson Ventures Trending on Pulse 2.0